AR123636A1 - Variantes de anticuerpos caninos - Google Patents
Variantes de anticuerpos caninosInfo
- Publication number
- AR123636A1 AR123636A1 ARP210102697A ARP210102697A AR123636A1 AR 123636 A1 AR123636 A1 AR 123636A1 AR P210102697 A ARP210102697 A AR P210102697A AR P210102697 A ARP210102697 A AR P210102697A AR 123636 A1 AR123636 A1 AR 123636A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- variants
- constant domain
- acid sequence
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084241P | 2020-09-28 | 2020-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123636A1 true AR123636A1 (es) | 2022-12-28 |
Family
ID=78599123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102697A AR123636A1 (es) | 2020-09-28 | 2021-09-28 | Variantes de anticuerpos caninos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12612454B2 (OSRAM) |
| EP (1) | EP4217384A2 (OSRAM) |
| JP (1) | JP2023543262A (OSRAM) |
| KR (1) | KR20230079148A (OSRAM) |
| CN (1) | CN116438196A (OSRAM) |
| AR (1) | AR123636A1 (OSRAM) |
| AU (1) | AU2021349301A1 (OSRAM) |
| BR (1) | BR112023005393A2 (OSRAM) |
| CA (1) | CA3194936A1 (OSRAM) |
| CL (2) | CL2023000878A1 (OSRAM) |
| CO (1) | CO2023004102A2 (OSRAM) |
| EC (1) | ECSP23030271A (OSRAM) |
| IL (1) | IL301413A (OSRAM) |
| MX (1) | MX2023003624A (OSRAM) |
| PE (1) | PE20231374A1 (OSRAM) |
| TW (1) | TW202229337A (OSRAM) |
| WO (1) | WO2022067233A2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022020944A2 (pt) * | 2020-04-17 | 2022-12-27 | Zoetis Services Llc | Variantes de anticorpos caninos |
| EP4217384A2 (en) | 2020-09-28 | 2023-08-02 | Zoetis Services LLC | Canine antibody variants |
| JP2025524441A (ja) * | 2022-06-21 | 2025-07-30 | ゾエティス・サービシーズ・エルエルシー | イヌ科動物抗体変異体 |
| EP4652197A1 (en) | 2023-01-20 | 2025-11-26 | Petmedix Ltd. | Therapeutic antibodies |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| WO2006031370A2 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| WO2012024650A2 (en) | 2010-08-19 | 2012-02-23 | Abbott Laboratories | Anti-ngf antibodies and their use |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JP6629069B2 (ja) | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | イヌ化抗ｎｇｆ抗体およびその方法 |
| EP4124624A3 (en) | 2013-12-20 | 2023-05-03 | Intervet International B.V. | Antibodies against canine pd-1 |
| US20210388053A1 (en) * | 2018-10-18 | 2021-12-16 | Kindred Biosciences, Inc. | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use |
| JP2022513653A (ja) * | 2018-11-28 | 2022-02-09 | ブリストル－マイヤーズ スクイブ カンパニー | 修飾された重鎖定常領域を含む抗体 |
| CN113227134A (zh) * | 2018-12-05 | 2021-08-06 | 株式会社梅花治疗 | 抗体的Fc区变体 |
| SG11202106478UA (en) | 2019-01-03 | 2021-07-29 | Invetx Inc | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| BR112022020944A2 (pt) * | 2020-04-17 | 2022-12-27 | Zoetis Services Llc | Variantes de anticorpos caninos |
| US20220119513A1 (en) | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| EP4217384A2 (en) | 2020-09-28 | 2023-08-02 | Zoetis Services LLC | Canine antibody variants |
-
2021
- 2021-09-28 EP EP21806440.0A patent/EP4217384A2/en active Pending
- 2021-09-28 MX MX2023003624A patent/MX2023003624A/es unknown
- 2021-09-28 TW TW110136032A patent/TW202229337A/zh unknown
- 2021-09-28 BR BR112023005393A patent/BR112023005393A2/pt unknown
- 2021-09-28 IL IL301413A patent/IL301413A/en unknown
- 2021-09-28 AU AU2021349301A patent/AU2021349301A1/en active Pending
- 2021-09-28 PE PE2023001231A patent/PE20231374A1/es unknown
- 2021-09-28 AR ARP210102697A patent/AR123636A1/es unknown
- 2021-09-28 KR KR1020237014355A patent/KR20230079148A/ko active Pending
- 2021-09-28 CA CA3194936A patent/CA3194936A1/en active Pending
- 2021-09-28 CN CN202180065886.6A patent/CN116438196A/zh active Pending
- 2021-09-28 JP JP2023519180A patent/JP2023543262A/ja active Pending
- 2021-09-28 WO PCT/US2021/052338 patent/WO2022067233A2/en not_active Ceased
- 2021-09-28 US US18/246,716 patent/US12612454B2/en active Active
-
2023
- 2023-03-27 CL CL2023000878A patent/CL2023000878A1/es unknown
- 2023-03-29 CO CONC2023/0004102A patent/CO2023004102A2/es unknown
- 2023-04-25 EC ECSENADI202330271A patent/ECSP23030271A/es unknown
-
2024
- 2024-02-29 CL CL2024000628A patent/CL2024000628A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116438196A (zh) | 2023-07-14 |
| CA3194936A1 (en) | 2022-03-31 |
| US20240010716A1 (en) | 2024-01-11 |
| AU2021349301A1 (en) | 2023-08-24 |
| US12612454B2 (en) | 2026-04-28 |
| TW202229337A (zh) | 2022-08-01 |
| BR112023005393A2 (pt) | 2023-04-25 |
| IL301413A (en) | 2023-05-01 |
| CL2023000878A1 (es) | 2023-10-20 |
| JP2023543262A (ja) | 2023-10-13 |
| ECSP23030271A (es) | 2023-07-31 |
| KR20230079148A (ko) | 2023-06-05 |
| PE20231374A1 (es) | 2023-09-07 |
| CL2024000628A1 (es) | 2024-07-19 |
| WO2022067233A3 (en) | 2022-05-27 |
| EP4217384A2 (en) | 2023-08-02 |
| WO2022067233A2 (en) | 2022-03-31 |
| CO2023004102A2 (es) | 2023-04-05 |
| MX2023003624A (es) | 2023-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107444A1 (es) | Composición farmacéutica que comprende constructos de anticuerpo biespecíficos | |
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| ZA202006432B (en) | T cell receptors | |
| EA201491186A1 (ru) | Полипептиды химерного фактора viii и их применение | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| CO2018002265A2 (es) | Anticuerpos anti-cd19 humano humanizados | |
| AR101936A1 (es) | Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas | |
| PE20200839A1 (es) | Anticuerpos anti-cd137 | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| AR123645A1 (es) | Variantes de anticuerpos felinos | |
| MX377605B (es) | Inmunoglobulina híbrida conteniendo un enlace no-peptidílico. | |
| AR101753A1 (es) | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO | |
| AR097405A1 (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a cd123 y cd3 y usos de los mismos | |
| EA201270517A1 (ru) | Микобактериальные вакцины | |
| CU20180129A7 (es) | Anticuerpos anti-basigin humanizados | |
| EA200300663A1 (ru) | Антагонисты cxcr3 | |
| PE20121722A1 (es) | Polipeptido de fusion contra tumor inducido por virus eb y mutante de colicina ia | |
| PE20211048A1 (es) | Anticuerpos injertados con peptido natriuretico tipo c | |
| MX364732B (es) | Vacuna contra el tumor de wilms 1. | |
| PE20211742A1 (es) | Anticuerpos agonistas de cd200r y sus usos | |
| EA201691004A1 (ru) | Последовательность модифицированного эндолизина kz144 | |
| MX2022003074A (es) | Anticuerpos anti-cd371, y usos de los mismos. | |
| MX2022008298A (es) | Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo. | |
| EA201792274A1 (ru) | Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения | |
| AR076083A1 (es) | Anticuerpo monoclonal anti-rhesus d |